Search Results

Stealth BioTherapeutics Inc. announced today that Reenie McCarthy, Stealth’s Chief Executive Officer, will participate in a fireside chat at the JMP Citizens Life Sciences Conference in New York on Monday, May 13 at 2:30 p.m. ET and participate in 1x1 meetings with investors.

Stealth BioTherapeutics today announced that the U.S. Food and Drug Administration (“FDA”) has now determined that its New Drug Application (“NDA”) for elamipretide for the treatment of Barth syndrome is entitled to a Priority Review designation.

Stealth BioTherapeutics Inc. today announced its participation at key upcoming ophthalmology conferences to discuss the Company’s clinical development efforts in dry age-related macular degeneration (dry AMD), including progression of lead investigational compound elamipretide into Phase 3 trials and development of pipeline compound bevemipretide (SBT-272) as a topical ophthalmic drop.

Stealth BioTherapeutics Inc. today announced that it has enrolled and dosed its first patient in the ReNEW trial ( NCT06373731 ) as part of its Phase 3 clinical program for elamipretide in patients with dry age-related macular degeneration (dry AMD).

Stealth BioTherapeutics today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing its New Drug Application (“NDA”) for elamipretide for the treatment of Barth syndrome.

Stealth BioTherapeutics Inc. announced today the presentation of new SBT-589 data demonstrating cardioprotective effects across pre-clinical models of Friedreich’s ataxia (FA).

Stealth BioTherapeutics Inc. today announced that Reenie McCarthy , Chief Executive Officer, and Brian Blakey , Chief Business Officer, will participate in a fireside chat at the Baird Biotech Discovery Series on Tuesday, December 5, 2023, at 11:30 AM ET.

Stealth BioTherapeutics Inc. today announced that Reenie McCarthy , Chief Executive Officer, will participate at OIS XIII: Ophthalmology Innovation Summit (OIS) taking place in San Diego, California on Saturday, December 2, at 11:05 AM PT.

Stealth BioTherapeutics Inc. today announced its achievement of target enrollment in the NuPOWER (SPIMD-301) study in patients with primary mitochondrial myopathy (PMM).

Hornet Therapeutics, a biotech company focused on developing treatments to address EBV-driven pathologies, emerges from stealth with the publication of data in the prestigious journal Science, which reports IDO-1 as a host enzyme hijacked by EBV.